Image de couverture de livre

The Future of Machine Learning Within Target Identification: Causality, Reversibility, and Druggability

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Jake P. Taylor‐King, Michael Bronstein, David Roblin
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Clinical Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Insights into Clinical Trials for Drugs Targeting MASLD: Progress, Challenges, and Future Directions
par: Yu Wu, et autres
Publié: (2025)

A Comparative Clinical Pharmacology Analysis of FDA‐Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology
par: Huy X. Ngo, et autres
Publié: (2024)

Methodology for Good Machine Learning with Multi‐Omics Data
par: Thibaud Coroller, et autres
Publié: (2024)

Machine Learning for Prediction of Drug Concentrations: Application and Challenges
par: Shuqi Huang, et autres
Publié: (2025)

Using Machine Learning to Individualize Treatment Effect Estimation: Challenges and Opportunities
par: Alicia Curth, et autres
Publié: (2024)

The Future of Clinical Translational Pharmacology
par: Matthew L. Rizk, et autres
Publié: (2026)

Artificial Intelligence/Machine Learning: The New Frontier of Clinical Pharmacology and Precision Medicine
par: Qi Liu, et autres
Publié: (2024)

Machine Learning and Artificial Intelligence in PK‐PD Modeling: Fad, Friend, or Foe?
par: Zhonghui Huang, et autres
Publié: (2024)

Characterizing Alzheimer’s Disease and Related Dementia in a Hypertension Population Within the State of Florida Using Electronic Health Record–Based Data
par: Eissa A. Jafari, et autres
Publié: (2025)

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development
par: Tanja S. Zabka, et autres
Publié: (2025)

Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID‐19 Under the Emergency Use Authorization
par: Qi Liu, et autres
Publié: (2024)

Epidemiological Characteristics, Target Distribution, and Clinical Value of Targeted Anticancer Drugs Approved in China: A Cross‐Sectional Study
par: Ting Zhu, et autres
Publié: (2026)

Identification of a Safe and Tolerable Carbamazepine Dosing Paradigm that Facilitates Effective Evaluation of CYP3A4 Induction
par: Amita Datta‐Mannan, et autres
Publié: (2024)

Machine Learning‐Based Prediction of Escitalopram and Sertraline Side Effects With Pharmacokinetic Data in Children and Adolescents
par: Ethan A. Poweleit, et autres
Publié: (2024)

Beyond Population‐Level Targets for Drug Concentrations: Precision Dosing Needs Individual‐Level Targets that Include Superior Biomarkers of Drug Responses
par: Thomas M. Polasek, et autres
Publié: (2024)

TMDD Modeling for Antibodies Directed Against Soluble Targets: Parameter Values for De Novo Modeling and Simulation From Experimental Data
par: Adam Nasim, et autres
Publié: (2026)

Machine Learning Prediction of Unbound Ceftriaxone Concentrations in Children: Capturing Developmental Changes in Protein Binding for Precision Dosing
par: Bo‐Hao Tang, et autres
Publié: (2026)

Causal Effects of Hydrophilic Bile Acids on Carfilzomib‐Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study
par: Samia Shabnaz, et autres
Publié: (2026)

Dose Optimization Informed by PBPK Modeling: State‐of‐the Art and Future
par: Karen Rowland Yeo, et autres
Publié: (2024)

Urinary Kidney Injury Biomarker Profiles in Healthy Individuals and After Nephrotoxic and Ischemic Injury
par: Sushrut S. Waikar, et autres
Publié: (2025)

Model‐Informed Precision Dosing Using Machine Learning for Levothyroxine in General Practice: Development, Validation and Clinical Simulation Trial
par: Jules M. Janssen Daalen, et autres
Publié: (2024)

Prediction of Acute Liver Injury Trajectory in Patients Following Acetaminophen Overdose: A Multibiomarker Machine Learning Proof‐of‐Concept Study
par: Chris Humphries, et autres
Publié: (2026)

Pathway‐Informed Machine Learning Identifies Genetic Predictors of High‐Dose Methotrexate‐Induced Mucositis in Pediatric Acute Lymphoblastic Leukemia
par: Xiao Yu Cindy Zhang, et autres
Publié: (2025)

Current Status and Future Directions in the Development of Digital Therapeutic Interventions for Neurodevelopmental Disorders
par: Hyun‐ju Lee, et autres
Publié: (2025)

Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay
par: Yi‐An Bi, et autres
Publié: (2024)

Innovations in Clinical Pharmacology: Shaping the Future of Evidence Generation in Research, Development, and Utilization of Medicines
par: Karthik Venkatakrishnan, et autres
Publié: (2025)

Assessment of Dosing Strategies for Pediatric Drug Products
par: Zachary L. Taylor, et autres
Publié: (2024)

Identification and Clinical Evaluation of Potential Biomarkers for Breast Cancer Resistance Protein (BCRP/ABCG2)
par: Andrew M. Riselli, et autres
Publié: (2025)

Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK/PD Modeling
par: Robin Thomas Ulrich Haid, et autres
Publié: (2024)

Quantification of Age and Sex Ratio Differences between Trial and Target Population for New Drugs
par: Miquel Serra‐Burriel, et autres
Publié: (2026)

A Pooled Population Pharmacokinetic Study of Oral and Intravenous Administration of Clavulanic Acid in Neonates and Infants: Targeting Effective Beta‐Lactamase Inhibition
par: Stef Schouwenburg, et autres
Publié: (2024)

Effect of Target‐Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic Function
par: Elise Burmeister Getz, et autres
Publié: (2025)

Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi‐Targeted/Functional Drugs Based on Clinicaltrials.gov
par: Chunhui Huang, et autres
Publié: (2024)

From Challenge to Opportunity: How Shwachman–Diamond Syndrome Became a Promising Target for Therapy Development
par: Eszter S. Hars, et autres
Publié: (2024)

Information Bias in Electronic Health Records and Administrative Claims Data: A Targeted Review of the Recent Literature
par: Patrick J. Arena, et autres
Publié: (2025)

Uncovering New Therapeutic Targets for Amyotrophic Lateral Sclerosis and Neurological Diseases Using Real‐World Data
par: Mohammadali Alidoost, et autres
Publié: (2025)

Microbiome‐Informed Dosing: Exploring Gut Microbial Communities Impact on Mycophenolate Enterohepatic Circulation and Therapeutic Target Achievement
par: Abdelrahman Saqr, et autres
Publié: (2025)

What African Patients, Clinicians, and Regulators Can Gain from Pharmacometrics: Forecasts for the Future in a New Era in Health
par: Steven E. Kern
Publié: (2025)

ISABELA Studies: Plasma Exposure and Target Engagement Do Not Explain the Lack of Efficacy of Ziritaxestat in Patients with Idiopathic Pulmonary Fibrosis
par: Amit Taneja, et autres
Publié: (2024)

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative
par: Joel L. Weissfeld, et autres
Publié: (2026)